VISTAGEN THERAPEUTICS, INC. Operating Lease, Expense
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Operating Lease, Expense of $3.50 thousand for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2023-08-10
- VISTAGEN THERAPEUTICS, INC. operating lease, expense for the quarter ending 2023-06-30 was $3.50K, a 0.00% change year-over-year.
- VISTAGEN THERAPEUTICS, INC. operating lease, expense for the quarter ending 2023-03-31 was -$617.40K.
- VISTAGEN THERAPEUTICS, INC. operating lease, expense for the quarter ending 2022-12-31 was $221.00K, a 176.94% increase year-over-year.
- VISTAGEN THERAPEUTICS, INC. operating lease, expense for the quarter ending 2022-09-30 was $213.50K, a 1.28% increase year-over-year.
- VISTAGEN THERAPEUTICS, INC. operating lease, expense for fiscal 2023 was $14.20K, a 0.00% change from fiscal 2022.
- VISTAGEN THERAPEUTICS, INC. operating lease, expense for fiscal 2022 was $14.20K, a 0.00% change from fiscal 2021.
- VISTAGEN THERAPEUTICS, INC. operating lease, expense for fiscal 2021 was $14.20K.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 3 month as first filed | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 9 month as first filed | Operating Lease, Expense 12 month |
|---|---|---|---|---|---|---|
| 2023-06-30 | $3.50K 10-Q · filed 2023-08-10 | -$613.90K derived: sum of 2 quarters · filed 2023-08-10 | -$392.90K derived: sum of 3 quarters · filed 2023-08-10 | -$179.40K derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2023-03-31 | -$617.40K derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-28 | -$396.40K derived: sum of 2 quarters · filed 2023-06-28 | -$182.90K derived: sum of 3 quarters · filed 2023-06-28 | $14.20K 10-K · filed 2023-06-28 | ||
| 2022-12-31 | $221.00K 10-Q · filed 2023-02-07 | $434.50K derived: sum of 2 quarters · filed 2023-02-07 | $631.60K 10-Q · filed 2023-02-07 | -$74.00K derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2022-09-30 | $213.50K 10-Q · filed 2022-11-10 | $410.70K 10-Q · filed 2022-11-10 | -$295.00K derived: sum of 3 quarters · filed 2023-08-10 | -$215.20K derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2022-06-30 | $3.50K 10-Q · filed 2023-08-10 | $197.20K 10-Q · filed 2022-08-11 | -$508.50K derived: sum of 2 quarters · filed 2023-08-10 | -$428.70K derived: sum of 3 quarters · filed 2023-08-10 | -$217.90K derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | -$512.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-28 | -$432.20K derived: sum of 2 quarters · filed 2023-06-28 | -$221.40K derived: sum of 3 quarters · filed 2023-06-28 | $14.20K 10-K · filed 2023-06-28 | ||
| 2021-12-31 | $79.80K 10-Q · filed 2023-02-07 | $290.60K derived: sum of 2 quarters · filed 2023-02-07 | $526.20K 10-Q · filed 2023-02-07 | $526.30K 10-Q · filed 2022-02-10 | -$86.90K derived: sum of 4 quarters · filed 2023-02-07 | |
| 2021-09-30 | $210.80K 10-Q · filed 2022-11-10 | $446.50K 10-Q · filed 2022-11-10 | -$166.70K derived: sum of 3 quarters · filed 2022-11-10 | $40.60K derived: sum of 4 quarters · filed 2022-11-10 | ||
| 2021-06-30 | $235.70K 10-Q · filed 2022-08-11 | -$377.50K derived: sum of 2 quarters · filed 2022-08-11 | -$170.20K derived: sum of 3 quarters · filed 2022-08-11 | $37.10K derived: sum of 4 quarters · filed 2022-08-11 | ||
| 2021-03-31 | -$613.20K derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-23 | -$405.90K derived: sum of 2 quarters · filed 2022-06-23 | -$198.60K derived: sum of 3 quarters · filed 2022-06-23 | $14.20K 10-K · filed 2022-06-23 | ||
| 2020-12-31 | $207.30K 10-Q · filed 2022-02-10 | $414.60K derived: sum of 2 quarters · filed 2022-02-10 | $627.40K 10-Q · filed 2022-02-10 | |||
| 2020-09-30 | $207.30K 10-Q · filed 2021-11-10 | $420.10K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |